Physician profile
Edwin Levine
NPI 1760441224
$1,388.36
in general payments reported to CMS, 2019-2025
14 companies · $201 in 2025
The $201 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.65 · 2020: $83.49 · 2021: $282 · 2022: $282 · 2023: $287 · 2024: $242 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $308.79 | 2022-2024 | |
| Boston Scientific Corporation | $302.33 | 2020-2022 | |
| Abbvie INC. | $276.05 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $167.76 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $65.59 | 2022-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $60.00 | 2021 | |
| Endogastric Solutions, INC | $57.45 | 2021 | |
| Aimmune Therapeutics, INC. | $38.62 | 2025 | Vowst |
| Celltrion USA INC. | $31.54 | 2025 | Vegzelma |
| Lilly USA, LLC | $18.41 | 2025 | Omvoh |
| Celgene Corporation | $17.22 | 2023 | Zeposia |
| Enterra Medical, INC. | $15.39 | 2022 | |
| Braintree Laboratories, INC. | $15.33 | 2024 | Suflave |
| Regeneron Healthcare Solutions, INC. | $13.88 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.